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Objective: Bacterial meningitis is a medical emergency associated with high mortality rates. Cerebrospinal fluid
(CSF) culture is the “gold standard” for diagnosis of meningitis and it is important to establish the susceptibility of
the causative microorganism to rationalize treatment. The Namibia Standard Treatment Guidelines (STGs)
recommends initiation of empirical antibiotic treatment in patients with signs and symptoms of meningitis after
taking a CSF sample for culture and sensitivity. The objective of this study was to assess the antimicrobial sensitivity
patterns of microorganisms isolated from CSF to antibiotics commonly used in the empirical treatment of
suspected bacterial meningitis in Namibia.
Methods: This was a cross-sectional descriptive study of routinely collected antibiotic susceptibility data from the
Namibia Institute of Pathology (NIP) database. Results of CSF culture and sensitivity from January 1, 2009 to May 31,
2012, from 33 state hospitals throughout Namibia were analysed.
Results: The most common pathogens isolated were Streptococcus species, Neisseria meningitidis, Haemophilus
influenzae, Staphylococcus, and Escherichia coli. The common isolates from CSF showed high resistance (34.3% –
73.5%) to penicillin. Over one third (34.3%) of Streptococcus were resistance to penicillin which was higher than
24.8% resistance in the United States. Meningococci were susceptible to several antimicrobial agents including
penicillin. The sensitivity to cephalosporins remained high for Streptococcus, Neisseria, E. coli and Haemophilus. The
highest percentage of resistance to cephalosporins was seen among ESBL K. pneumoniae (n = 7, 71%–100%), other
Klebsiella species (n = 7, 28%–80%), and Staphylococcus (n = 36, 25%–40%).
Conclusions: The common organisms isolated from CSF were Streptococcus Pneumoniae, Neisseria meningitidis,
Haemophilus influenzae, Staphylococcus, and E. coli. All common organisms isolated from CSF showed high
sensitivity to cephalosporins used in the empirical treatment of meningitis. The resistance of the common isolates
to penicillin is high. Most ESBL K. pneumoniae were isolated from CSF samples drawn from neonates and were
found to be resistant to the antibiotics recommended in the Namibia STGs. Based on the above findings, it is
recommended to use a combination of aminoglycoside and third-generation cephalosporin to treat non–ESBL
Klebsiella isolates. Carbapenems (e.g., meropenem) and piperacillin/tazobactam should be considered for treating
severely ill patients with suspected ESBL Klebsiella infection. Namibia should have a national antimicrobial resistance
surveillance system for early detection of antibiotics that may no longer be effective in treating meningitis and
other life-threatening infections due to resistance.
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Bacterial meningitis is an acute infection in which the
meninges, the subarachnoid space, and the brain paren-
chyma are all frequently involved in the inflammatory
reaction. This disease is characterized by severe head-
ache, fever, intolerance to light and sound and rigidity of
muscles, especially those of the neck. The central
nervous system (CNS) inflammatory reaction from bac-
terial meningitis may result in decreased consciousness,
seizures, raised intracranial pressure, and stroke [1].
Bacterial meningitis is a medical emergency. The
therapeutic goal is to initiate antibiotic therapy within
60 minutes of a patient’s arrival in the emergency room.
In patients suspected of having bacterial meningitis,
cerebrospinal fluid (CSF) should be obtained for cultures
and empirical antimicrobial therapy initiated without
delay [2,3]. Diagnosis of bacterial meningitis is con-
firmed by CSF culture the “gold standard” for diagnosis
of meningitis and it is equally important to obtain the
antimicrobial susceptibility of the causative microorgan-
ism to rationalize treatment [4,5].
The organisms most commonly responsible for
community-acquired bacterial meningitis are Streptococ-
cus pneumoniae, Neisseria meningitidis, Streptococci
group B, Listeria monocytogenes, and Haemophilus influ-
enza [6,7]. In children, meningococcal, Haemophilus
influenzae type b (Hib), and pneumococcal infections
are the most common causes [7].
Specific antibiotic treatment for bacterial meningitis
depends upon identification of the causative organism.
More than 80% of patients with common bacterial men-
ingitis are culture positive. However, CSF culture positiv-
ity decreases with prior antibiotic treatment before
lumbar puncture [4].
As infections of the CNS are potentially life threaten-
ing, empirical therapy should be initiated promptly
whenever bacterial meningitis is a major diagnostic con-
sideration. The Namibia Standard Treatment Guidelines
(STGs) recommend initiation of empirical antibiotics
treatment in patients with signs and symptoms of men-
ingitis after taking a CSF sample for analysis, culture,
and antibiotic sensitivity testing. The preferred medi-
cines for patient with signs and symptoms of meningitis
are based on knowledge of the common causative agent
of meningitis in the specific patient group and the sensi-
tivity of the suspected pathogen to the commonly used
antimicrobials.
However, many infectious diseases are becoming
increasingly difficult to treat because of antimicrobial-
resistant organisms. Both the epidemiology of bacterial
meningitis and the sensitivity to antibiotics are changing
as a result of the widespread use of antimicrobials and
other factors [4]. Antimicrobial susceptibility data among
CNS pathogens is therefore important to effectivelymanage meningitis patients in the first critical hours of
their treatment [8]. Empirical antibiotic therapy should be
adjusted to local drug resistance patterns and clinical sub-
groups. Accurate information regarding the important
etiological agents and populations at risk is necessary to
ascertain public health measures and ensure appropriate
management of bacterial meningitis [9,10].
It is therefore essential to monitor the emergence of
resistance to antibiotics that are used for the empirical
treatment as delay in providing effective treatment may
adversely affect a patient’s treatment outcome.
Objectives
 To determine the common microorganisms isolated
from cerebrospinal fluid that are responsible for
infectious meningitis in Namibia
 To establish the prevalence of antimicrobial
sensitivity of microorganisms isolated from clinical
cerebrospinal fluid samples in Namibia
 To determine the most appropriate medicines for
the treatment of meningitis in Namibia
Methods
This was a cross-sectional descriptive study using rou-
tinely collected antibiotic susceptibility data from
Namibia Institute of Pathology (NIP) database. Results
of CSF culture and sensitivity from January 1, 2009 to
May 31, 2012, from 33 out of 35 state hospitals through-
out Namibia were stored in Meditech®. NIP uses this
commercial laboratory management software to capture
routinely collected antibiotic susceptibility and other la-
boratory data from public sector health facilities
throughout the country. Cerebrospinal fluid clinical
samples were transported and immediately processed at
the NIP’s regional or central laboratory. Standard CSF
bacterial culture is accomplished using horse blood agar
(5%) or chocolate agar.
Pathogen identification and antibacterial susceptibil-
ities were performed as appropriate using Wellcogen®
Bacterial Antigen Kit, Gram stain, and methylene blue
stain. Standard antibiogram profile tests were done for
specific microorganism isolates with some variations
according to the doctors’ request. Culture results were
read after 24 hours of incubation. Plates were re-
incubated for a further 24 hours and re-examined for
additional organisms. The results were recorded on a
worksheet and entered into Meditech. Printed results
were sent back to the clinicians who could also obtain
the results by logging into the tool’s web-based reporting
module.
WHONET, a database software developed by the World
Health Organization Collaborating Centre for Surveillance
of Antimicrobial Resistance, was used to extract the data
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thorough visual checks and preliminary frequency counts
on the raw data set and identified errors were corrected
by the lead author. Cleaned data was analysed using Sta-
tistical Package for the Social Sciences® version 12.0.1.
The main outcome variable was the proportion of sam-
ples with positive cultures of suspected microorganisms.
We also looked into the sensitivity patterns of isolates
from CSF. Descriptive statistics were used to summarize
the frequencies and distributions of microbial isolates and
their sensitivity to various antimicrobials.
Since the analysis was conducted on de-identified elec-
tronic records of samples tested by the NIP, individual
patient consent was not required. Authorization to con-
duct the analysis was granted by the Permanent Secre-
tary of Ministry of Health and Social Services of
Namibia (MoHSS) and the NIP management.
Results
A total of 7,267 CSF samples were tested at the NIP cen-
tral and regional laboratories for culture and antimicro-
bial sensitivity. Out of the 7,267 CSF samples submitted,
701 (9.6%) showed growth of microorganisms. Out of
the 701 samples with growth of microorganism, 503
(71.8%) grew bacteria, 188 (26.8%) grew fungi (mainly
Cryptococcus), and the remaining 10 samples (1.4%)
grew mycobacterium (Table 1).
The most frequent gram positive organisms isolated
were Streptococcus species (n = 206, 40.9%), Staphylococ-
cus (n = 36, 7.2%), and Enterococcus species (n = 9, 1.8%).
The three most frequently identified gram negative
organisms isolated were Neisseria meningitidis (N.
meningitidis) (n = 107, 21.3%), Haemophilus influenzae
(n = 59, 11.7%), and Escherichia coli (E. coli) (n = 22,
4.4%) (Table 2).
Extended spectrum beta lactamase (ESBL) Klebsiella
pneumoniae (K. pneumonia) was the most frequently
isolated microorganism in CSF samples collected from
neonates (4/9) whereas Haemophilus, Streptococcus, and
Staphylococcus were common in CSF samples collected
from infants aged from one to 11 months. In the age
group 1–5 years, Neisseria, Haemophilus, and Strepto-
coccus were commonly isolated (Table 3). Neisseria andTable 1 Type of organism isolated from CSF
Type of organism Frequency (%) Cumulative (%)
Gram Negative 239 (3.3%) 239 (3.3%)
Gram Positive 264 (3.6%) 503 (6.9%)
Fungi 188 (2.6%) 691 (9.5%)
Mycobacterium 10 (0.1%) 701 (9.6%)
No growth 6,566 (90.4%) 7,267 (100.0%)
Total 7267 (100.0%)
Source: MEDITECH Database 2009–2012.Streptococcus were commonly isolated in CSF samples
drawn from the age group 6–12 years. In adults and
adolescents 12 years and older, Neisseria, E. coli, Strepto-
coccus, and Staphylococcus were the most frequent isolates
(Table 3). The majority of the isolated bacteria (n = 409,
81.3%) were from inpatient CSF samples, followed by
samples from the outpatient (n = 40, 8.0%) and paediatrics
departments (n = 43, 8.5%) (Table 4).
We found that Streptococcus species were the most
common gram positive organisms isolated from clinical
CSF samples analyzed by NIP. Streptococci showed very
high resistance to sulfamethoxazole/trimethoprim (n =
125, 71.4%) and high resistance to oxacillin (n = 69,
45.1%), penicillin (n = 58, 34.3%), and amoxicillin (n = 6,
25.0%). Streptococci were moderately resistant for genta-
micin, tetracycline, clindamycin, and erythromycin, ran-
ging from 12.4 to 20.0%. The resistance to ceftriaxone,
ofloxacin, cefuroxime, chloramphenicol, and vancomycin
ranged from 2.2% to 5.5%. All of the bacterial isolates
(n = 34, 100.0%) that were tested for ciprofloxacin were
found to be sensitive to this medicine (Table 5).
Among the gram negative bacteria, N.meningitidis was
the most frequently isolated pathogen, and showed the
following patterns of resistance sulfamethoxazole/tri-
methoprim (n = 79, 77.5%), erythromycin (n = 4, 28.6%),
penicillin (n = 16, 15.2%), tetracycline (n = 3, 12.5%),
cefuroxime (n = 5, 4.8%), and chloramphenicol (n = 3,
2.9%) (Table 5).
Haemophilus isolates were resistant to sulfamethoxa-
zole/trimethoprim (n = 25, 67.6%), amoxicillin (n = 18,
34%), cefuroxime (n = 5, 25%), amoxicillin/clavulanic
acid (n = 4, 22.2%), tetracycline (n = 4, 14.8%), chloram-
phenicol (n = 6, 10.9%), and ceftriaxone (n = 5, 9.6%). All
Haemophilus isolates were sensitive to penicillin G and
ciprofloxacin (Table 5).
Staphylococcus isolates showed relatively high resistance
to most antibiotics ranging from 25.0% to 78.6%. The
highest rate of resistance was for amoxicillin (n = 11,
78.6%) followed by penicillin (n = 25, 73.5%), sulfameth-
oxazole/trimethoprim (n = 18, 62.1%), gentamicin (n = 9,
52.9%) and cefuroxime (n = 2, 40%). The resistance to
cloxacillin, oxacillin, ofloxacin, erythromycin, tetracycline,
and cephalothin ranged between 34.5%–25%. Staphylococ-
cus were less resistant to fusidic acid (n = 1, 2.9%). All
staphylococcus isolates were found to be sensitive to
vancomycin and amikacin (Table 5).
Most E. coli isolates were resistant to sulfamethoxa-
zole/trimethoprim (n = 18, 85.7%) and amoxicillin (n = 19,
86.4%). E. Coli showed resistance to piperacillin/tazobactam,
tetracycline, amoxicillin/clavulanic acid, penicillin and
erythromycin ranging between 25%–50%. On the other
hand, E. Coli showed lower rates of resistance to gentamicin
(n = 3, 17.65%), cefuroxime (n = 2, 10.5%), cephalothin
(n = 1, 10%), and ciprofloxacin (n = 1, 7.7%). All E. Coli









187 37.18 187 37.18
Neisseria meningitids
group A
53 10.54 240 47.71
Neisseria meningitidis 48 9.54 288 57.26
Haemophilus
influenzae
38 7.55 326 64.81
Escherichia coli 22 4.37 348 69.18
Staphylococcus
aureus
19 3.78 367 72.96
Haemophilus species 15 2.98 382 75.94
Staphylococcus
epidermides
10 1.99 392 77.93
Streptococcus
species
10 1.99 402 79.92
Enterococcus faecalis 7 1.39 409 81.31
ESBL Klebsiella
pneumoniae
7 1.39 416 82.7
Haemophilus
influenzae type B
6 1.19 422 83.9
Pseudomonas
aeruginosa
5 0.99 427 84.89
Streptococcus group
B
4 0.8 431 85.69
Acinetobacter
baumanii
4 0.8 435 86.48
Klebsiella
pneumoniae
4 0.8 439 87.28
Bacillus cereus 3 0.6 442 87.87
Micrococcus species 3 0.6 445 88.47
Gram negative bacilli 3 0.6 448 89.07
Serratia liquifaciens 3 0.6 451 89.66
Gram positive cocci 2 0.4 453 90.06
Listeria
monocygenes
2 0.4 455 90.46
Staphylococcus
capitis
2 0.4 457 90.85
Staphylococcus
haemolyticus
2 0.4 459 91.25
Streptococcus group
A
2 0.4 461 91.65
Streptococcus
viridans group
2 0.4 463 92.05
Acinetobacter lwoffii 2 0.4 465 92.45
ESBL’s Escherichia
coli
2 0.4 467 92.84
Klebsiella oxytoca 2 0.4 469 93.24
Neisseria meningitidis
group C
2 0.4 471 93.64
Neisseria meningitidis
W135
2 0.4 473 94.04
Table 2 Bacteria isolated from CSF (Continued)
Neisseria species 2 0.4 475 94.43
Salmonella species 2 0.4 477 94.83
Serratia marcescens 2 0.4 479 95.23
Sphingomonas
paucimobilis
2 0.4 481 95.63
Bacillus species 1 0.2 482 95.83
Diphtheroid
organisms
1 0.2 483 96.02
Enterococcus
faecium
1 0.2 484 96.22
Enterococcus species 1 0.2 485 96.42
Kocuria varians 1 0.2 486 96.62
Staphylococcus
hominis
1 0.2 487 96.82
Staphylococcus
saprophyticus
1 0.2 488 97.02
Staphylococcus
simulans
1 0.2 489 97.22
Streptococcus
agalacteae
1 0.2 490 97.42
Acinetobacter junii 1 0.2 491 97.61
Acinetobacter
species
1 0.2 492 97.81
Aeromonas
hydrophilia
1 0.2 493 98.01
Coliform bacillus 1 0.2 494 98.21
Enterobacter species 1 0.2 495 98.41
Haemophilus
parainfluenzae
1 0.2 496 98.61
Klebsiella ozaenae 1 0.2 497 98.81
Moraxella species 1 0.2 498 99.01
Morganella morganii 1 0.2 499 99.2
Pseudomonas
paucimobilis
1 0.2 500 99.4
Pseudomonas
species
1 0.2 501 99.6
Salmonella
omnivalent positive
1 0.2 502 99.8
Yersinia pestis 1 0.2 503 100
Source: MEDITECH Database 2009–2012.
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Table 3 Frequency of organisms isolates by age group
Organism <1 mo 1-11 mos 1-55 yrs 6-12 yrs > 12 yrs Age Unk Total % of total
Streptococcus pneumoniae 2 31 27 17 87 42 187 37.18
Neisseria species 2 5 14 18 56 12 107 21.27
Haemophilus species 0 18 24 2 9 6 59 11.73
Staphylococcus 0 10 6 2 11 7 36 7.16
Others Gram negative 0 11 2 0 7 2 22 4.39
Escherichia coli 1 2 1 0 15 3 22 4.37
Streptococcus species 19 3.77
Other Gram positives 0 4 3 1 5 0 13 2.6
Enterococcus species 0 3 0 2 1 3 9 1.79
Acinetobacter species 0 4 0 2 2 0 8 1.59
ESBL’s Klebsiella pneumoniae 4 2 0 0 0 1 7 1.39
Klebsiella 0 1 1 0 4 1 7 1.39
Pseudomonas species 0 2 2 1 2 0 7 1.39
Total 9 93 80 45 199 77 503 100.02
Source: MEDITECH Database 2009–2012. Legend: mo=month; mos=months; yrs=years; age unk= age unknown; % = percent.
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amphenicol (Table 5).
Klebsiella isolates were resistant to cephalothin (n = 4,
80.0%), amoxicillin (n = 4, 57.1%), sulfamethoxazole/tri-
methoprim (n = 4, 57.1%), cefuroxime (n = 2, 33.3%), and
piperacillin/tazobactam (n = 1, 33.3%). All Klebsiella (n = 5,
100%) showed sensitivity to ciprofloxacin. However, the
ESBL-K. pneumonia isolates (n = 7) were resistant to nearly
all commonly used antibiotics such as amoxicillin, ceftriax-
one, cefuroxime, gentamicin, and sulfamethoxazole/tri-
methoprim (Table 5).Table 4 Frequency of organisms isolated by hospital departm
Organism Inpatient Outpatie
Streptococcus species 162 16
Neisseria species 94 11
Haemophilus species 47 2
Staphylococcus aureus 34 1
Escherichia coli 13 7
Other Gram negative 20 2
Other Gram positive 12 0
Enterococcus species 8 0
Acinetobacter species 6 0
ESBL’s Klebsiella pneumoniae 6 1
Klebsiella 7 0
Pseudomonas species 0 0
Total 409 (81.3%) 40 (8.0%)
Source: MEDITECH Database 2009–2012.Discussion
The study was aimed at determining the antimicrobial
sensitivity patterns of common microorganisms isolated
from clinical samples of CSF and to recommend appro-
priate medicines for the empirical treatment of meningi-
tis in Namibia.
There are several laboratory tests that are useful in the
diagnosis of central nervous system infection, yet no single
laboratory test or clinical feature can distinguish between
different types of central nervous system infections. Some
clinicians propose clinical decision rules which combineent













43 (8.5%) 11 (2.2%) 503 (100%)
Table 5 Susceptibility of organisms isolated from CSF
Organism Antimicrobial Total, N S S, % R R, % I I, %
Streptococcus 206 isolates Ciprofloxacin 34 34 100 0 0 0
Ceftriaxone 89 87 97.8 2 2.2 0 0
Ofloxacin 40 39 97.5 1 2.5 0 0
Cefuroxime 28 27 96.4 1 3.6 0 0
Chloramphenicol 171 160 93.6 9 5.3 2 1.2
Vancomycin 110 102 92.7 6 5.5 2 1.8
Erythromycin 186 162 87.1 23 12.4 1 0.5
Clindamycin 140 120 85.7 19 13.6 1 0.7
Tetracycline 180 146 81.1 25 13.9 9 5
Gentamicin 5 4 80 1 20 0 0
Amoxicillin 24 18 75 6 25 0 0
Penicillin 169 109 64.5 58 34.3 2 1.2
Oxacillin 153 79 51.6 69 45.1 5 3.3
Sulfamethoxazole/trimethoprim 175 48 27.4 125 71.4 2 1.1
Neisseria meningitidis 107 isolates Chloramphenicol 102 97 95.1 3 2.9 2 2
Ceftriaxone 105 97 92.4 5 4.8 3 2.9
Penicillin 105 86 81.9 16 15.2 3 2.9
Erythromycin 14 10 71.4 4 28.6 0 0
Tetracycline 24 17 70.8 3 12.5 4 16.7
Sulfamethoxazole/trimethoprim 102 22 21.6 79 77.5 1 1
Haemophilus 59 isolates Amoxicillin 53 32 60.4 18 34 3 5.7
Amoxicillin/Clavulanic Acid 18 14 77.8 4 22.2 0
Ceftriaxone 52 46 88.5 5 9.6 1 1.9
Cefuroxime 20 14 70 5 25 1 5
Chloramphenicol 55 48 87.3 6 10.9 1 1.8
Ciprofloxacin 11 11 100 0 0 0
Ofloxacin 23 22 95.7 0 0 1 4.3
Penicillin 6 6 100 0 0
Tetracycline 27 21 77.8 4 14.8 2 7.4
Sulfamethoxazole/trimethoprim 37 10 27 25 67.6 2 5.4
Staphylococcus 36 isolates Amikacin 7 7 0 0 0 0 0
Vancomycin 22 20 90.9 0 0 2 9.1
Fusidic acid 34 29 85.3 1 2.9 4 11.8
Ciprofloxacin 21 17 81 4 19 0
Cephalothin 8 6 75 2 25 0 0
Clindamycin 27 19 70.4 6 22.2 2 7.4
Tetracycline 27 19 70.4 8 29.6 0
Erythromycin 31 21 67.7 10 32.3 0 0
Oxacillin 9 6 66.7 3 33.3 0 0
Cloxacillin 29 19 65.5 10 34.5 0
Cefuroxime 5 3 60 2 40 0 0
Gentamicin 17 7 41.2 9 52.9 1 5.9
Penicillin 34 8 23.5 25 73.5 1 2.9
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Table 5 Susceptibility of organisms isolated from CSF (Continued)
Amoxicillin 14 3 21.4 11 78.6 0 0
Sulfamethoxazole/trimethoprim 29 0 0 18 62.1 11 37.9
Escherichia coli 22 isolates Ceftriaxone 17 17 100 0 0
Chloramphenicol 6 6 100 0 0
Ciprofloxacin 13 12 92.3 1 7.7 0
Cefuroxime 19 15 78.9 2 10.5 2 10.5
Piperacillin-Tazobactam 4 3 75 1 25 0
Cephalothin 10 7 70 1 10 2 20
Gentamicin 17 11 64.71 3 17.65 3 17.65
Tetracycline 5 3 60 2 40 0
Amoxicillin/Clavulanic Acid 7 4 57.14 3 42.86 0.0
Erythromycin 4 2 50 2 50 0
Penicillin 4 2 50 2 50 0
Sulfamethoxazole/trimethoprim 21 3 14.29 18 85.71 0
Amoxicillin 22 3 13.6 19 86.4 0
Enterococcus species 9 isolates Penicillin 8 7 87.5 1 12.5 0 0
Vancomycin 9 7 77.8 1 11.1 1 11.1
Amoxicillin 7 5 71.4 2 28.6 0 0
Ciprofloxacin 3 2 66.7 1 33.3 0
Erythromycin 3 1 33.3 2 66.7 0 0
Clindamycin 8 2 25 6 75 0 0
Tetracycline 2 0 0 2 100 0 0
Sulfamethoxazole/trimethoprim 2 0 0 2 100 0 0
Acinetobacter species 8 isolates Imipenem 8 7 87.5 1 12.5 0
Sulfamethoxazole/trimethoprim 7 6 85.7 1 14.3 0
Gentamycin 8 6 75 2 25 0 0
Piperacillin-Tazobactam 8 6 75 1 12.5 1 12.5
Ceftazidime 6 4 66.7 1 16.7 1 16.7
Piperacillin 2 1 50 1 50 0
Klebsiella 7 isolates Ciprofloxacin 5 5 100 0 0
Amikacin 6 5 83.3 1 16.7 0
Ceftriaxone 7 5 71.4 2 28.6 0
Gentamicin 6 4 66.7 1 16.7 1 16.7
Piperacillin-Tazobactam 3 2 66.7 1 33.3 0
Cefuroxime 6 3 50 2 33.3 1 16.7
Sulfamethoxazole/trimethoprim 7 3 42.9 4 57.1 0
Cephalothin 5 1 20 4 80 0 0
Amoxicillin 7 1 14.3 4 57.1 2 28.6
ESBL’s Klebsiella pneumoniae 7 isolates Amikacin 7 5 71.43 1 14.3 1 14.3
Ciprofloxacin 7 7 100 0 0
Imipenem 7 7 100 0 0
Piperacillin-Tazobactam 7 7 100 0 0
Ceftazidime 7 2 28.6 5 71.4 0
Amoxicillin 7 0 7 100 0
Ceftriaxone 7 0 7 100 0
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Table 5 Susceptibility of organisms isolated from CSF (Continued)
Cefuroxime 7 0 7 100 0
Gentamicin 7 0 7 100 0
Sulfamethoxazole/trimethoprim 7 0 7 100 0
Pseudomonas species 7 isolates Amikacin 7 7 100 0 0
Ceftazidime 7 7 100 0 0
Ciprofloxacin 6 6 100 0 0
Imipenem 6 6 100 0 0
Gentamycin 6 5 83.3 1 16.7 0 0
Piperacillin-Tazobactam 7 4 57.1 0 3 42.9
Sulfamethoxazole/trimethoprim 7 3 42.9 4 57.1 0
Source: MEDITECH Database 2009–2012. legend: S=sensitive; R=resistant and I=indeterminate.
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culture and identification remain the gold standard for
diagnosing bacterial meningitis [11,12].
The etiology of central nervous system infections
differs from place to place and with different age groups
[13,14]. Studies have shown that bacterial meningitis is
responsible for about 30%– 40% of central nervous sys-
tem infections. The remaining 60-70% are due to other
etiologies such as viral meningitis, cryptococcal meningi-
tis, brain abscess, tuberculosis meningitis, tuberculoma
and others [13,15].
In this analysis, 9.6% of the CSF samples showed
microorganism growth. Studies have shown that CSF
cultures are expected to be positive in 70%–85% of
patients with bacterial meningitis who had no prior anti-
microbial therapy [4,15,16]. In the present study, prior
antibiotic treatment and high aseptic meningitis associ-
ated with HIV may have contributed to the low bacteria
growth [4,16]. Autoimmune processes, HIV itself, and men-
ingitis caused by fungal infections that occur in patients
with late stage HIV infection can present with signs and
symptom of meningitis with negative CSF culture [17].
The most common pathogens causing meningitis that
were isolated from the CSF samples analysed by NIP
were Streptococcus species, N. meningitidis, Haemophilus
influenzae, Staphylococcus, and E. coli. All common
organisms isolated from CSF the samples showed high
resistance to penicillin. The 34.3% resistance of Strepto-
coccus species to penicillin is much higher than the
24.8% resistance in the United States [18]. This is sur-
prising as resistance rates are generally expected to be
higher in developed countries [19].
The sensitivity to cephalosporins remained high for
Streptococcus, Neisseria, E. coli, and Haemophilus. The
96.4% sensitivity of S. pneumoniae for cefuroxime was
comparable with 91.4% sensitivity in the United States
[20] The highest percentage of resistance to a cephalo-
sporin was seen among ESBL K. pneumoniae, Klebsiella,
and Staphylococcus.The profile of isolated organisms differed by age
group. Staphylococcus seemed to be the common cause
of meningitis in all age groups. Staphylococcus was mod-
erately sensitive (60%–75%) to the cephalosporins
(cefuroxime, cephalothin) but it showed less sensitivity
to penicillins (23.5%) and zero sensitivity to sulfameth-
oxazole/trimethoprim which is not used in the empirical
treatment of patients with suspected meningitis.
ESBL K. pneumoniae was the most frequent isolate in
CSF samples drawn from neonates (4/9). This finding is dif-
ferent from the known common pathogens that cause
meningitis during the first week of life in the United States
[4]. There has been a significant increase in ESBL Klebsiella
species reported in recent years [21,22]. These strains are
highly virulent and have an extraordinary ability to spread,
and can result in bacteremia and significantly increase mor-
tality. Klebsiellae have been incriminated in nosocomial
infections [21,22]. ESBL Klebsiella has become a major
problem in hospitals because of resistance to multiple
antibiotics [22]. In addition to meningitis, it can cause
pneumonia, bacteremia, thrombophlebitis, urinary tract
infection, cholecystitis, diarrhea, upper respiratory tract
infection, wound infection, osteomyelitis, and meningitis.
The medical use of invasive devices, contamination of
respiratory support equipment and use of antibiotics are
factors that increase the likelihood of nosocomial infec-
tion with Klebsiella species. Sepsis and septic shock may
follow entry of organisms into the blood from a focal
source. The Namibia STGs recommend empirical treat-
ment of suspected meningitis in children younger than
three months with amoxicillin combined with gentami-
cin as first choice and ceftriaxone as alternative. Yet, the
ESBL’s Klebsiella isolate was found to be sensitive to cip-
rofloxacin, imipenem, and piperacillin/tazobactam and
resistant to almost all the medicines included in the
Namibia STGs, such as amoxicillin and gentamicin.
Most of the ESBL K. pneumoniae were isolated from
CSF samples drawn from neonates. Haemophilus species
were common isolate in one month to 11 months and
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Staphylococcus were common in CSF samples drawn
from infants aged from one month to 11 months
whereas Streptococcus, Neisseria, and Haemophilus were
commonly isolated in the 1–5 years age group. In the
6–12 years age group, Neisseria and Streptococcus were
the most common isolate. Streptococcus pneumoniae,
Neisseria specie, Escherichia coli and Staphylococcus were
common isolate in adults. Streptococcus pneumoniae and
Neisseria specie were common isolate in all age group
and were found to be sensitive to cephalosporins
recommended in the STGs (ceftriaxone and cefuroxime).
However, 40.0% of Staphylococci and 25.0% of Haemophi-
lus isolates were resistant to cefuroxime. Staphylococcus
and Haemophilus species were also found to be resistant
to amoxicillin in 78.6% and 34.0% of the cases. Staphylo-
cocci and Haemophilus were second and third common
isolate in infants aged one month to 11 months following
Streptococcus pneumoniae. Other studies have indicated
that 80% of community-acquired bacterial meningitis in chil-
dren aged three months and older are due to S. pneumoniae
and N. meningitidis and empirical coverage with cephalo-
sporin (cefuroxime or ceftriaxone) is recommended [10].
In adults and adolescents, Streptococcus and Neisseria
were the most frequent isolates—this is consistent with
the finding of other similar studies [10]. Both have high
sensitivity to ceftriaxone.
Strengths and implications
The strength of this epidemiologic analysis is that it pro-
vided the national picture of microorganisms causing
CNS infection and their resistance pattern. It also showed
the common isolate among different age group and their
resistance pattern. These finding can be used to guide em-
pirical treatment of patients with suspected meningitis. It
can also inform the review of treatment guidelines. This
exercise demonstrated the importance of analyzing rou-
tinely collected clinical laboratory data in the monitoring
of the emergence of antimicrobial resistance. The analysis
was time efficient and inexpensive. The analysis can be
replicated on other clinical conditions to identify the com-
mon causative organism or repeated at a later date to see
trends in antimicrobial resistance patterns.
Limitations
The main limitation of this analysis was the use of
secondary data. The data was not primarily collected to
answer a specific a priori research question but as part
of NIP’s routine testing clinical samples. The laboratory
tests’ results are recorded mainly for reporting back to
clinicians as well for administrative and billing purposes.
As a result of this set up, not all species of microbes
were identified or tested against the antibiotics of inter-
est. There were also some important variables notcaptured in the system, including the possible alternative
diagnoses and a patient’s history of prior treatment with
antibiotics before collection the CSF samples.
Conclusions
The common organisms isolated from CSF samples sub-
mitted to the NIP were Streptococcus Pneumoniae,
Neisseria meningitidis, Haemophilus influenzae, Staphylo-
coccus, and E. coli. All common organisms isolated from
CSF showed high sensitivity to the cephalosporins used in
the empirical treatment of meningitis in Namibia. The
resistance of common isolates to penicillin which is alter-
native to cephalosporins in the STG is high.
Most ESBL K. pneumoniae isolated from CSF samples
were from neonates and were found to be resistant to the
antibiotics recommended in the Namibia STGs for
treating meningitis in children aged three months or
younger. Based on the above findings, it is recommended
to use a combination of aminoglycoside and third-
generation cephalosporin to treat non–ESBL Klebsiella
isolates. Carbapenems (e.g., meropenem) and piperacillin/
tazobactam should be considered in severely ill patients
with possible ESBL Klebsiella infection.
There is a need to strengthen the infection control
practices in the public hospitals in Namibia. It is also
recommended that a national antimicrobial resistance
surveillance system be developed for early detection of
resistance. This would be expected to help identify
appropriate antibiotics for the management of meningi-
tis in Namibia.
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